Skip to content
Mitochondrial-Derived Peptide

Humanin

The first mitochondrial-derived peptide ever identified — a 24-amino-acid signal encoded in the mitochondrial 16S rRNA gene. Circulating levels fall with age and run higher in the children of centenarians, and its analogue HNG improves metabolic markers in middle-aged mice. No trial has ever given humanin to people: every human finding is a blood level, not an intervention.

longevityneuroprotectionmetabolic-healthcellular-repair
Tier C— Use caution — limited human data
Evidence gradeD — Anecdotal / In vitro only
BH

Reviewed & fact-checked by

BiohackingHub Research Team

Editorial Research Team · Last updated: October 3, 2026

Verified

What Humanin Is

Humanin is a 24-amino-acid peptide encoded by a short open reading frame inside the mitochondrial 16S ribosomal RNA gene. It was found in 2001, in a functional screen for genes that could rescue neurons from death caused by familial Alzheimer's disease mutations and by amyloid-beta. The rescue depended on the exact sequence of the peptide, and the peptide was secreted into the culture medium — the first sign that it behaves as a signal rather than a structural part.

That discovery mattered beyond neurology. Mitochondrial DNA had been read for decades as a 37-gene genome with no room for anything else. Humanin showed that a ribosomal RNA gene could hide a second, protein-coding message. MOTS-c, found in the 12S rRNA gene in 2015, and six small humanin-like peptides (SHLPs) from the same 16S region followed. The class is explained in full in Humanin and MOTS-c: Mitochondrial-Derived Peptides Explained.

What the Evidence Actually Shows

Cells. Humanin binds Bax, an apoptosis-inducing protein, and stops it moving to the mitochondrial membrane. Reducing humanin with small interfering RNA made cells more sensitive to Bax. This is a 2003 Nature finding and it is the mechanistic core of every cytoprotection claim.

Rats. Using hyperinsulinaemic clamps, a 2009 study showed that humanin infused into the brain improved whole-body insulin sensitivity through hypothalamic STAT-3. Intravenous analogues reproduced the effect, and a single dose of a potent analogue lowered blood glucose in Zucker diabetic fatty rats.

Worms and mice. In C. elegans, overexpressing humanin was sufficient to extend lifespan, dependent on daf-16/FOXO. Middle-aged mice treated twice weekly with the analogue HNG showed better metabolic healthspan markers and lower inflammatory markers. Note what that sentence does not say: it does not say the mice lived longer.

Humans — observation only. Circulating humanin declines with age. Children of centenarians carry much higher levels than age-matched controls. Levels are lower in Alzheimer's disease and in MELAS. Treatment with growth hormone or IGF-1 lowered humanin in human subjects.

What Humanin Has Never Shown

  • Any effect when given to a person. No published trial has administered humanin or HNG to humans. Every human data point is a measured blood level.
  • A human dose. There is none. Rodent doses were given by injection or infused into the brain.
  • A lifespan extension in mammals. The lifespan result is in worms. The mouse result is healthspan markers.
  • Long-term safety. A peptide whose central mechanism is blocking programmed cell death has an obvious open question about cancer, and nobody has answered it.
  • That low levels cause disease. Lower humanin in Alzheimer's and higher humanin in centenarians' children are associations. A marker that tracks ageing is not proven to drive it.

Why It Is Graded D

Humanin has serious science behind it — PNAS, Nature, clamp studies, a multi-species ageing paper. What it lacks is a single interventional human data point. On this site, grade D means exactly that: mechanism and animal evidence only. The grade describes the state of human evidence, not the quality of the laboratories.

The safety tier is C for the same reason. The peptide may well be benign. But "unknown in humans, sold without regulatory oversight, anti-apoptotic by design" cannot honestly be rated higher.

What You Can Do About Humanin Today

You cannot buy a validated humanin intervention. You can do the one thing shown to raise mitochondrial-derived peptides in people: exercise. A 2021 review of the human studies concluded that acute high-intensity exercise can increase humanin and MOTS-c in skeletal muscle and plasma, while the evidence for lasting changes from training is conflicting.

That is why humanin appears in the Mito-Peptide Advanced protocol as a research tier with no dose — a compound to follow in the literature, not a step to take. The protocol's working layers are exercise, cofactors with human trials, and MOTS-c as an optional, clearly labelled experimental layer.

Related Research

Stacking Interactions

How Humanin interacts with other compounds

=
MOTS-cNeutralanecdotal evidence

The two best-characterised mitochondrial-derived peptides, encoded in neighbouring rRNA genes. Complementary on paper — humanin is cytoprotective, MOTS-c is metabolic — but the combination has no study in any species

=
Coenzyme Q10Neutralanecdotal evidence

CoQ10 is the mitochondrial intervention with human outcome trials. Nothing links it mechanistically to humanin; it is simply the layer that has evidence

!
Growth hormone secretagoguesCautionweak evidence

GH and IGF-1 lowered circulating humanin in humans. Anyone raising the GH axis while paying for a humanin vial is pulling the same lever in two directions

Protocols using Humanin

Evidence-graded stacks that include this compound

Safety Profile — Tier C

Use caution — limited human data

Contraindications

  • ●Any current or previous cancer — humanin suppresses apoptosis by blocking Bax, and no human study has examined what that does to tumour cells
  • ●Pregnancy and breastfeeding — no human data
  • ●Use outside a registered clinical study — there is no approved product, no established human dose and no pharmaceutical-grade supply

Side Effects

  • ●Unknown in humans — no administration study has been published
  • ●Injection-site reactions are expected with any subcutaneous peptide
  • ●Purity and identity of grey-market vials are unverified by any regulator

Drug Interactions

Growth hormone and IGF-1 therapy — both lowered circulating humanin in human subjects; the clinical meaning is unknownChemotherapy and other pro-apoptotic cancer treatments — a Bax inhibitor is a theoretical antagonist; no interaction study existsInsulin and glucose-lowering drugs — humanin analogues lowered glucose in diabetic rats; the human effect is unstudied